Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

The addition of durvalumab (Imfinzi)and bevacizumab (Avastin) to transarterial chemoembolization (TACE) led to a significant improvement in progression-free survival (PFS) vs TACE alone in patients with unresectable hepatocellular carcinoma (HCC) eligible for embolization, according to findings from the phase 3 EMERALD-1 trial (NCT03778957) that were presented at the 2024 Gastrointestinal Cancers Symposium.

At the final PFS analysis, the median PFS was 15.0 months (95% CI, 11.1-18.9) with durvalumab and bevacizumab plus TACE (n = 204) vs 8.2 months (95% CI, 6.9-11.1) with TACE alone (n = 205), resulting in a 23% reduction in the risk of progression or death with the 2 systemic therapies (HR, 0.77; 95% CI, 0.61-0.98; P = .032) and meeting the study’s primary end point. The 12- and 18-month PFS rates were 55.5% and 43.1% with durvalumab and bevacizumab vs 39.8% and 28.3% with TACE alone, respectively. Similar PFS benefit was seen across most prespecified subgroups.

“Durvalumab plus bevacizumab in combination with TACE has the potential to set a new standard of care in [patients with] unresectable HCC eligible for embolization,” Riccardo Lencioni, MD, lead study author and professor in the Department of Surgery, Medical, Molecular, and Critical Area Pathology at Università di Pisa in Italy, said in a presentation of the data.

For more than 2 decades, TACE has been a standard treatment for patients with embolization-eligible, unresectable HCC despite the commonality of disease progression within 1 year of therapy. Investigators hypothesized that the addition of durvalumab and/or bevacizumab could lead to prolonged tumor response as TACE may prime the tumor microenvironment for immunotherapy and VEGF inhibitors via neoantigen release and ischemia.

The double-blind, global, placebo-controlled trial enrolled patients eligible for embolization with measurable HCC per modified RECIST criteria, Child-Pugh A to B7 liver function, an ECOG performance status of 0 or 1, and no evidence of extrahepatic disease. Patients who were candidates for curative therapy with surgical resection, ablation, or transplantation; those who received prior systemic therapy or TACE; and those with grade 3 or 4 portal vein thrombosis were excluded from enrollment.

Dosing Schedules In EMERALD-1

Eligible patients (n = 616) were randomly assigned 1:1:1 to durvalumab plus TACE (arm A), durvalumab plus bevacizumab and TACE (arm B), or TACE alone (arm C). The protocol allowed investigator’s choice of conventional TACE or TACE with drug-eluting beads. Patients received 1500 mg of durvalumab (arm A and B) or placebo (arm C) every 4 weeks plus TACE, after which they received 1120 mg of durvalumab plus placebo (arm A), 15 mg/kg of bevacizumab (arm B), or placebo for both agents every 3 weeks (arm C).

Durvalumab and placebo were administered during the TACE period, which consisted of 1 to 4 TACE procedures within 16 weeks according to the investigator’s discretion. The second phase of therapy began at week 16 and was continued until progressive disease, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria were met.

The primary end point was PFS for the durvalumab, bevacizumab, and TACE arm vs the TACE and durvalumab arm. Secondary end points included PFS for durvalumab plus TACE vs TACE alone, overall survival (OS), objective response rate (ORR), time to progression (TTP), safety, and quality of life. PFS, ORR, and TTP were evaluated according to blinded independent central review by RECIST 1.1 criteria.

Patients underwent imaging for tumor assessment at week 12 and every 9 weeks thereafter. Stratification factors included TACE modality (drug-eluting bead TACE vs conventional TACE), geographical region (Japan vs Asia vs other), and portal vein invasion (Vp1 or Vp2+ / -Vp1 vs none).

Examining Patient Characteristics

Demographic and baseline features were generally well balanced across arms. Most patients in the durvalumab and bevacizumab arm had Barcelona Clinic Liver Cancer stage B disease (57.4%) followed by stage A (25.0%) and stage C (17.2%). More than half of patients across arms A, B, and C received conventional TACE (59.4%; 58.3%; 58.5%). Approximately half of the patients received treatment in Asia (52.1%; 52.4%; 52.1%), and most patients did not have portal vein invasion (93.7%; 92.2%; 93.7%).

Across all 3 arms, most patients had received 1 or 2 TACE procedures. A total of 43.6%, 42.5%, and 40.0% of patients in the durvalumab and bevacizumab, durvalumab, and TACE-alone arms remain on study, respectively, and 14.0%, 13.0%, and 13.5% of whom continue to receive durvalumab.

The data cutoff date for the final PFS analysis, presented here with an approximate target maturity of 72%, and the interim OS analysis, was September 11, 2023. At the time of data cutoff, OS was not statistically significant and the approximate target maturity was 51%.

Additional Findings Show Improvements With Combination

Results showed that the median PFS with the addition of durvalumab to TACE in patients (n = 207) was 10.0 months (95% CI, 9.0-12.7) vs 8.2 months (95% CI, 6.9-11.1) with TACE alone, failing to meet the secondary end point for PFS (HR, 0.94; 95% CI, 0.75-1.19; P = .638).

The median TTP was improved with the addition of durvalumab and bevacizumab to TACE vs TACE alone but not with durvalumab alone. The median TTP was 22.0 months (95% CI, 16.6-24.9) with durvalumab and bevacizumab vs 10.0 months (95% CI, 7.1-13.6) with TACE alone (HR, 0.63; 95% CI, 0.48-0.82). The median TTP was 11.5 months (95% CI, 9.2-13.9) with durvalumab vs 10.0 months (95% CI, 7.1-13.6) with TACE alone (HR, 0.89; 95% CI, 0.69-1.15).

Regarding responses, the ORR was 43.6% with durvalumab and bevacizumab, 41.0% with durvalumab, and 29.6% with TACE alone, with odds ratios of 1.87 (95% CI, 1.24-2.84) and 1.67 (95% CI, 1.10-2.54) for durvalumab and bevacizumab vs TACE and durvalumab vs TACE, respectively. Notably, complete responses across the 3 arms were rare, comprising 3.0%, 1.5%, and 2.5% of the ORRs in the durvalumab/bevacizumab, durvalumab, and TACE-alone arms, respectively. Stable disease lasting at least 20 weeks occurred in 22.3%, 20.5%, and 31.0% of patients, respectively.

The median duration of response was 22.1 months (lower quartile-upper quartile [LQ-UQ], 11.2-30.3), 14.0 months (LQ-UQ, 6.9-30.7), and 16.4 months (LQ-UQ, 6.3-26.3) with durvalumab and bevacizumab, durvalumab, and TACE alone, respectively.

“The median time from the start of TACE to the first dose of the combination therapy was similar across the 3 arms [at approximately 3 months],” Lencioni said. “However, the duration of exposure was longer in the post-TACE period as well as across the total study in the durvalumab and bevacizumab arm, consistent with the PFS in these patients.”

The study remains blinded to investigators and participants and follow-up will continue for OS.

Exploring Safety With The Regimens

Regarding safety, no new signals were identified. Within the safety analysis sets of the durvalumab and bevacizumab (n = 154), durvalumab (n = 232), and TACE alone (n = 200) arms, 45.5%, 27.6%, and 23.0% of patients had grade 3 or 4 adverse effects (AEs). AEs leading to discontinuation occurred in 24.7%, 12.1%, and 7.0% of patients, respectively. Deaths occurred in the durvalumab and bevacizumab, bevacizumab, and TACE alone arms at rates of 10.4% (n = 38), 9.1% (n = 28), and 5.5% (n = 14), respectively.

The most common treatment-emergent AEs (TEAEs) of any grade reported in the durvalumab and bevacizumab arm included hypertension (27.3%), postembolization syndrome (26.6%), hypothyroidism (22.7%), pruritus (21.4%), proteinuria (21.4%), and constipation (18.8%). Grade 3/4 TEAEs in this arm included hypertension (5.8%), anemia (4.5%), acute kidney injury (3.9%), proteinuria (3.9%), postembolization syndrome (3.2%), hepatic encephalopathy (3.2%), ascites (2.6%), hyponatremia (2.6%), and esophageal varices hemorrhage (2.6%).

“The incidence of AEs was consistent with the duration of treatment exposure and the known safety profiles of durvalumab, bevacizumab, and TACE, and the incidence of maximum grade 3 or 4 AEs was low across all arms,” Lencioni concluded.

Disclosures: Lencioni reported having a consulting or advisory role with AstraZeneca, Bayer, Eisai, and Roche.

Reference

Lencioni R, Kudo M, Erinjeri J, et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J Clin Oncol. 2024;42(suppl 3):LBA432. doi:10.1200/JCO.2024.42.3_suppl.LBA432